PMC8488083_01
Lung adenocarcinoma shown by radiologic and pathologic examinations. (A) Chest CT scan reveals a mass in right lung. (B) Hematoxylin and eosin staining shows a low differentiation adenocarcinoma (HE x 100).
fmed-08-649177-g0001.jpg
PMC8488083_01_fmed-08-649177-g0001.jpg
F1
The chest computed tomography (CT) showed a mass in the right lung (7.6 cm x 5.8 cm) with multiple enlarged lymph nodes in mediastinum (Figures 1A, 2). Percutaneous lung biopsy was performed, and atypical cells were observed (Figure 1B).
Timeline of diagnosis and treatment of the patient, with CT and MRI scans of lesions during the treatment of crizotinib additionally provided.
fmed-08-649177-g0002.jpg
PMC8488083_01_fmed-08-649177-g0002.jpg
F2
The chest computed tomography (CT) showed a mass in the right lung (7.6 cm x 5.8 cm) with multiple enlarged lymph nodes in mediastinum (Figures 1A, 2). Tumors v1.1. The follow-up CT examinations at 5 and 7 months after treatment showed that the lung lesion was stable compared with previous examinations (Figure 2). The MRI revealed an iso-signal shadow with a diameter of 0.8 cm and 2.1 cm in the right frontal lobe and parietal lobe, respectively, suggesting metastatic lesions in the brain (Figure 2).
(A) Sequencing reads of SDC4 and ROS1 are shown by the Integrative Genomics Viewer, and Schematic representation of the SDC4- ROS1 fusion protein domain structure. (B) The Integrative Genomics Viewer snapshot of ROS1-GK fusion. Schematic representation of the ROS1-GK fusion protein domain structure. Orange, SDC4; blue, ROS1; blue, ROS1; cyan, ADGRG6.
fmed-08-649177-g0003.jpg
PMC8488083_01_fmed-08-649177-g0003.jpg
F3
A total of five somatic mutations were detected (Table 1), including SDC4-ROS1(EX2:EX32) and ROS1-GK (EX31:EX13) double ROS1 rearrangements with mutant allele frequency of 7.0 and 7.8%, respectively (Figure 3).